TREATMENT OF CENTRAL NERVOUS SYSTEM DISEASES BY ANTIBODIES AGAINST GLATIRAMER ACETATE

Abstract of the Disclosure

The present invention provides humanized polyclonal and 5 humanized monoclonal antibodies directed against an epitope on glatiramer acetate, also known as Copolymer 1, Copolymer-1, Cop-1 or Cop. Additionally, the subject invention concerns a pharmaceutical composition comprising an antibody directed against an epitope on glatiramer acetate for the 10 treatment of a disease associated with demyelination of central nervous system axons. Also encompassed by the subject invention is a method of treating a subject suffering from a disease associated with demyelination of central nervous system axons. The subject invention further contains 15 methods of stimulating remyelination of central nervous system axons. In addition, the subject invention provides a method of stimulating proliferation of lymphocytes.